By Fineline Cube 
China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that its investigational product, GR1802 injection, has received clinical trial approval from the National Medical Products Administration (NMPA) for the treatment of seasonal allergic rhinitis in adolescents. This marks a significant milestone in advancing innovative therapies for adolescent patients suffering from this condition.
GR1802 Injection: A Novel Therapeutic Approach
GR1802 injection is a recombinant, fully human anti-IL-4Rα monoclonal antibody independently developed by Chongqing Genrix Bio Pharmaceutical. The product targets IL-4Rα, a key mediator of allergic and inflammatory responses. GR1802 specifically binds to human IL-4Rα on the cell surface, blocking the binding of IL-4 and IL-13 to IL-4Rα. This inhibition prevents downstream STAT6 phosphorylation and CD23 upregulation, effectively suppressing Th2-type inflammatory responses mediated by IL-4 or IL-13.
Clinical Development Overview
Prior to this approval for seasonal allergic rhinitis in adolescents, GR1802 injection had already received clinical trial approvals for several other indications. The product is currently in Phase III clinical trials for moderate to severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, and allergic rhinitis. Additionally, GR1802 is in a Phase II clinical trial for asthma and a Phase Ib/II clinical trial for atopic dermatitis in children and adolescents.-Fineline Info & Tech